Mascia Adverse Effects of Anti-EGFR Therapy Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of

help guide further investigation in this area. the search for ways to prevent this disruptive side effect. The current studies provide mechanistic insights that should Additional work will be necessary to further expand our understanding of EGFR inhibitor toxicity and to continue skin macrophages may contribute to the adverse effects of EGFR inhibitors. studies suggest that EGFR signaling is important for normal skin barrier function and antimicrobial defense and that and immune cell types to determine which ones are necessary for the rash phenotype. The findings of these two investigated the effects of crossing mice that lack EGFR in the skin with mice deficient in different immune pathways patients and study animals and examined the effects of EGFR inhibition on skin defenses and bacteria. They also patients treated with EGFR inhibitors. They characterized the changes in chemokine expression in the skin of treated Both sets of authors used mouse models that lack EGFR only in the skin to replicate the pattern of injury seen in this phenomenon. to mechanism of rash formation induced by EGFR inhibitors and uncover some of the skin components that contribute . help clarify the et al . and Lichtenberger et al prematurely stop their treatments. Now, two papers by Mascia inhibitors are particularly known for causing a severe rash and skin damage, which sometimes forces patients to correlates with its side effects, as is the case for inhibitors of the epidermal growth factor receptor (EGFR). EGFR body. This can be difficult to achieve for cancer drugs, however, especially when the effectiveness of a drug directly The goal of all medical interventions is to treat disease while minimizing the damage to healthy tissues in the Skin-Deep Search for the Effects of EGFR Inhibitors

[1]  J. Fischer,et al.  Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.

[2]  M. Washington,et al.  Epidermal growth factor receptor inhibits colitis-associated cancer in mice. , 2012, The Journal of clinical investigation.

[3]  M. Gnant,et al.  Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. , 2012, Cancer treatment reviews.

[4]  Raphael Kopan,et al.  The black box illuminated: signals and signaling. , 2012, The Journal of investigative dermatology.

[5]  T. Mizoguchi,et al.  Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells , 2012, The Journal of Immunology.

[6]  L. Gleaves,et al.  A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis , 2011, The Journal of Immunology.

[7]  Wei-Li Di,et al.  Inflammatory skin and bowel disease linked to ADAM17 deletion. , 2011, The New England journal of medicine.

[8]  R. Seethala,et al.  Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. , 2011, Oral oncology.

[9]  M. Washington,et al.  Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. , 2011, The Journal of clinical investigation.

[10]  M. Lacouture,et al.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities , 2011, Supportive Care in Cancer.

[11]  J. Verweij,et al.  Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. , 2010, European journal of cancer.

[12]  M. Steinhoff,et al.  Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. , 2010, Journal of the American Academy of Dermatology.

[13]  Yoon-Koo Kang,et al.  Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines , 2010, The British journal of dermatology.

[14]  U. Rodeck,et al.  Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. , 2009, Cancer Research.

[15]  B. De Moor,et al.  Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Van Cutsem,et al.  Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.

[17]  D. Threadgill,et al.  Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor , 2009, Genesis.

[18]  Andrew Snyder Is there a silver lining? l , 2008 .

[19]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[20]  Gary Clark,et al.  Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies , 2007, Clinical Cancer Research.

[21]  M. Lacouture Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[22]  Y. Komiyama,et al.  Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib , 2006, Journal of Cancer Research and Clinical Oncology.

[23]  J. Segre,et al.  Epidermal barrier formation and recovery in skin disorders. , 2006, The Journal of clinical investigation.

[24]  K. Nishio,et al.  Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. , 2005, Lung cancer.

[25]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Vidal,et al.  A keratin K5Cre transgenic line appropriate for tissue‐specific or generalized cre‐mediated recombination , 2004, Genesis.

[27]  E. Wagner,et al.  Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart , 2003, Development.

[28]  G. Girolomoni,et al.  Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. , 2003, The American journal of pathology.

[29]  S. Akira,et al.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. , 1998, Immunity.

[30]  K. Ley,et al.  Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Magnuson,et al.  Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. , 1997, The American journal of pathology.

[32]  O. Smithies,et al.  Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Ullrich,et al.  Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.

[34]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[35]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[36]  D. Priebat,et al.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.